Search research articles
Contact Us
Filters
Showing results (81-90 of 143) with videos related to
Page
of 15
Sort By:
British Journal of Haematology
|
October 4, 2007
Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma
Owen A O'Connor, Paul A Hamlin, Carol Portlock, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 7, 2022
The Impact of Semiautomatic Segmentation Methods on Metabolic Tumor Volume, Intensity, and Dissemination Radiomics in <sup>18</sup>F-FDG PET Scans of Patients with Classical Hodgkin Lymphoma
Julia Driessen, Gerben J C Zwezerijnen, Heiko Schöder, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 25, 2011
Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma
John Gerecitano, Carol Portlock, Paul Hamlin, et al.
British Journal of Haematology
|
September 22, 2016
Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma
Scott D Ramsey, Auayporn Nademanee, Tamas Masszi, et al.
Leukemia & Lymphoma
|
January 7, 2020
Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis
Pier Luigi Zinzani, Robert Chen, Philippe Armand, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
September 2, 2014
Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma
Parastoo B Dahi, Roni Tamari, Sean M Devlin, et al.
Blood
|
December 21, 2011
Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma
Craig H Moskowitz, Matt J Matasar, Andrew D Zelenetz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2009
Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies
Owen A O'Connor, Steven Horwitz, Paul Hamlin, et al.
International Journal of Radiation Oncology, Biology, Physics
|
May 4, 2018
The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group
Louis S Constine, Joachim Yahalom, Andrea K Ng, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
December 10, 2013
A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients
Craig S Sauter, Juliet N Barker, Lauren Lechner, et al.
Page
of 15
Search research articles
Search
Showing results (81-90 of 143) with videos related to
Sort By:
Page
of 15
British Journal of Haematology
|
October 4, 2007
Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma
Owen A O'Connor, Paul A Hamlin, Carol Portlock, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 7, 2022
The Impact of Semiautomatic Segmentation Methods on Metabolic Tumor Volume, Intensity, and Dissemination Radiomics in <sup>18</sup>F-FDG PET Scans of Patients with Classical Hodgkin Lymphoma
Julia Driessen, Gerben J C Zwezerijnen, Heiko Schöder, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 25, 2011
Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma
John Gerecitano, Carol Portlock, Paul Hamlin, et al.
British Journal of Haematology
|
September 22, 2016
Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma
Scott D Ramsey, Auayporn Nademanee, Tamas Masszi, et al.
Leukemia & Lymphoma
|
January 7, 2020
Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis
Pier Luigi Zinzani, Robert Chen, Philippe Armand, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
September 2, 2014
Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma
Parastoo B Dahi, Roni Tamari, Sean M Devlin, et al.
Blood
|
December 21, 2011
Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma
Craig H Moskowitz, Matt J Matasar, Andrew D Zelenetz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2009
Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies
Owen A O'Connor, Steven Horwitz, Paul Hamlin, et al.
International Journal of Radiation Oncology, Biology, Physics
|
May 4, 2018
The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group
Louis S Constine, Joachim Yahalom, Andrea K Ng, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
December 10, 2013
A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients
Craig S Sauter, Juliet N Barker, Lauren Lechner, et al.
Page
of 15